Platelet I1-imidazoline binding sites are elevated in depression but not generalized anxiety disorder

• Published in: Journal of psychiatric research 1996-05, Vol.30 (3), p.147-168
• Main Authors: PILETZ, J. E, HALARIS, A, NELSON, J, QU, Y, BARI, M
• Format: Article
• Language: English
• Subjects: Adult; Adult and adolescent clinical studies; Anxiety Disorders - blood; Binding Sites; Biological and medical sciences; Biomarkers - blood; Blood Platelets - chemistry; Clonidine - metabolism; Depression; Depressive Disorder - blood; Desipramine - metabolism; Female; GTP-Binding Proteins - metabolism; Humans; Imidazoline Receptors; Male; Medical sciences; Middle Aged; Mood disorders; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Receptors, Adrenergic, alpha-2 - drug effects; Receptors, Adrenergic, alpha-2 - metabolism; Receptors, Drug - blood
• ISSN: 0022-3956
• DOI: 10.1016/0022-3956(96)00005-2

Depressed patients have been reported to have a higher than normal density of platelet binding sites for 3H-clonidine, an alpha 2-adrenoceptor agonist. Paradoxically, other studies using 3H-alpha 2, antagonists have found no differences from controls. Because 3H-clonidine interacts with platelet alpha 2-adrenoceptors to form G-protein complexes, whereas 3H-alpha 2-antagonists bind with uncoupled receptors, an elevation in G-protein coupling might explain this paradox. Another possibility is that depression might be associated with increased non-adrenergic I1-imidazoline binding sites, which are also clonidine sensitive. To distinguish these possibilities, we utilized p125I-clonidine to measure density (Bmax) and affinity (KD) of platelet G-protein coupled alpha 2-adrenoceptors as well as platelet I1 binding sites, and compared diagnostic groups of major depressive disorder (MDD), generalized anxiety disorder (GAD) and healthy subjects. Specific inhibition of binding by norepinephrine (NE = 10 microM) was used to selectively quantify alpha 2-adrenoceptors, whereas inhibition by 10 microM moxonidine (a > 100-fold selective I1 ligand) quantified I1 binding sites under a NE mask. I1 sites were found to be markedly elevated by, on average, +136% in MDD patients (p = .0007), whereas there was only a marginal increase in alpha 2-adrenoceptor Bmax values in MDD patients (p = .08; GAD and healthy subjects did not differ). Treatment of MDD patients for 6-8 weeks with desipramine downregulated I1 sites as well as alpha 2-adrenoceptors. Positive correlations were also noted for both sites: (a) between Bmax values and the severity of depression (using the Hamilton Depression Rating Scale); and (b) between end-of-treatment plasma desipramine concentrations and the extent of downregulation in Bmax values when subject groups were pooled. None of the binding parameters was associated with plasma catecholamine concentrations. The results suggest that an increased density of platelet I1 binding sites may partially explain the utility of radiolabeled clonidine as a potential biological marker for depressive illness, although an additional increase in G-protein coupling cannot be excluded.